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Abstract
Introduction Mammographically dense breast tissue is a strong
predictor of breast cancer risk, and is influenced by both
mitogens and mutagens. One enzyme that is able to affect both
the mitogenic and mutagenic characteristics of estrogens is
cytochrome P450 1A2 (CYP1A2), which is principally
responsible for the metabolism of 17β-estradiol.
Methods In a cross-sectional study of 146 premenopausal and
149 postmenopausal women, we examined the relationships
between CYP1A2 activity, malondialdehyde (MDA) levels, and
mammographic density. In vivo CYP1A2 activity was assessed
by measuring caffeine metabolites in urine. Levels of serum and
urinary MDA, and MDA–deoxyguanosine adducts in DNA were
measured. Mammograms were digitized and measured using a
computer-assisted method.
Results CYP1A2 activity in postmenopausal women, but not in
premenopausal women, was positively associated with
mammographic density, suggesting that increased CYP1A2
activity after the menopause is a risk factor for breast cancer. In
premenopausal women, but not in postmenopausal women,
CYP1A2 activity was positively associated with serum and
urinary MDA levels; there was also some evidence that CYP1A2
activity was more positively associated with percentage breast
density when MDA levels were high, and more negatively
associated with percentage breast density when MDA levels
were low.
Conclusion These findings provide further evidence that
variation in the activity level of enzymes involved in estrogen
metabolism is related to levels of mammographic density and
potentially to breast cancer risk.
Keywords: caffeine metabolic ratio, CYP1A2, malondialdehyde, malondialdehyde deoxyguanosine adducts, mammographic density
Introduction
Increased amounts of stromal and epithelial tissue in the
breast is a strong independent risk factor for breast cancer,
and they appear as light areas on a mammogram because
they are radiologically dense. These areas are referred to as
'mammographic density'. In contrast, fat appears dark on a
mammogram because it is radiologically lucent [1].
Like breast cancer, epidemiologic evidence for breast den-
sity suggests that endocrine factors play a role [1]. Mam-
mographic density levels decline with increasing age, onset
of menopause, increasing body weight and parity, and
younger age at first childbirth [1]. Density levels increase
with hormone replacement therapy [2], and are reduced
with tamoxifen [3] and a gonadotrophin release agonist [4].
In addition to mitogens, mammographic density may also
be influenced by mutagens. Relationships between mam-
mographic density and the mutagen malondialdehyde
(MDA), an end product of lipid peroxidation, have been
observed in two studies [5,6], suggesting that breast den-
sity levels are also affected by mutagenic events that can
AAMU = 5-acetylamino-6-amino-3-methyluracil; AFMU = 5-acetylamino-6-formylamino-3-methyluracil; BMI = body mass index; CMR = caffeine met-
abolic ratio; CYP1A2 = cytochrome P450 1A2; dG-MDA = malondialdehyde–deoxyguanosine (adducts); HPLC = high-performance liquid chroma-
tography; MDA = malondialdehyde; 1U = 1-methylurate; 1, 7U = 1,7-dimethylurate; 1X = 1-methylxanthine; WHR = waist–hip ratio.Breast Cancer Research    Vol 6 No 4    Hong et al.
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lead to DNA damage [7,8]. and increased cell proliferation
[9]. The main DNA adduct is malondialdehyde–deoxygua-
nosine (dG-MDA), and this and other MDA adducts are
twofold to threefold greater in breast tissue from patients
with breast cancer than in breast tissue from those without
breast cancer [10]. Increased levels of circulating MDA
have also been detected in breast cancer patients com-
pared with noncancer patients [11].
Of human P450s that are capable of oxidizing estradiol,
cytochrome P450 1A2 (CYP1A2) has the highest catalytic
activity, resulting in the production of 2-hydroxy and 4-
hydroxy metabolites. The absolute level of 2-hydroxylation
of estrone, which is mediated by CYP1A2, is six to seven
times greater than the extent of 4-hydroxylation mediated
by this enzyme [12]. Although CYP1A2 is a hepatic enzyme
that is not expressed in the breast, it can potentially affect
circulating estrogen levels. Circulating sex hormone levels,
in turn, have been shown in prospective studies of post-
menopausal women to be associated with future risk for
developing breast cancer [13]. Differences in CYP1A2
mRNA levels in human liver have also been reported, and it
has been suggested that these differences in CYP1A2
expression may play a role in various cancers [14,15]. Fig-
ure 1 shows the estrogen metabolites resulting from
CYP1A2 function and how these metabolites may poten-
tially have an impact on breast density levels [16]. Of these
metabolites, 4-hydroxyestrogens are known to be estro-
genic and are thought to be carcinogenic. Most studies
agree, however, that 2-hydroxyestrogens are not danger-
ous because the metabolite is nonestrogenic and has been
determined to be non-tumorigenic in animal models [17].
Catecholestrogens can contribute to carcinogenesis by
becoming a source of reactive oxygen species and entering
into redox cycling (i.e. repeated cycles of oxidation and
reduction between catechol and quinone estrogens). In
particular, 4-hydroxyestrogens can become a source of
potentially genotoxic and cytotoxic reactive oxygen species
[16,18] because they can be oxidized by numerous
enzymes into compounds called 3, 4-semiquinones and 3,
4-quinones. These compounds are highly reactive and can
bind to DNA to create depurinating adducts that induce
gene mutations and may lead to tumor initiation. The 2-cat-
echolestrogens, in contrast, are oxidized to form predomi-
nantly stable DNA adducts, which remain in DNA unless
they are removed by repair processes [18].
The goals of the present cross-sectional study of premeno-
pausal and postmenopausal women were to determine
whether CYP1A2 activity is associated with mammo-
graphic density, whether CYP1A2 activity is related to
MDA levels (serum, urinary, and dG-MDA), and whether
MDA levels are associated with breast density.
Figure 1
Estrogen metabolism by cytochrome P450 1A2 (CYP1A2) and its postulated effects on catecholestrogen levels and mammographic density Estrogen metabolism by cytochrome P450 1A2 (CYP1A2) and its postulated effects on catecholestrogen levels and mammographic density. 
aCYP1A2 is principally responsible for metabolizing 17β-estradiol after an initial conversion to estrone. The enzyme is primarily involved in 2- and 4-
hydroxylations. bIn humans, between 40% and 50% of estrogens undergo 2-hydroxylation whereas 5–8% undergo 4-hydroxylation. cCatecholestro-
gens are deactivated by catechol-O-methyltransferase (COMT). dCatecholestrogens can potentially affect breast density levels through estrogen-
receptor mediated mechanisms and/or oxidative mechanisms. 2-Hydroxyestrogens are nonestrogenic and nontumorigenic, but can be oxidized to 
form predominantly stable DNA adducts. 4-Hydroxyestrogens are estrogenic and carcinogenic. They form potentially genotoxic and cytotoxic reac-
tive oxygen species (ROS) that can bind to DNA to create depurinating adducts. ROS can also participate in lipid peroxidation to create the muta-
gen malondialdehyde (MDA), which is a risk factor for mammographic density. These mechanisms are postulated to be inhibitory (-) or stimulatory 
(+) for development of mammographic density.Available online http://breast-cancer-research.com/content/6/4/R338
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Methods
The methods for this study are published in detail else-
where [19] and are only briefly described here. Ethical
approval for the study protocol was given by the Human
Subjects Review Committee at the University of Toronto,
Canada.
Source of study subjects
Between 1994 and 1997, potential participants were iden-
tified from the mammographic units of Mount Sinai,
Women's College, and St. Michael's Hospital in Toronto.
The extent of mammographic density for all patients was
visually estimated by a radiologist and expressed as a per-
centage of breast area on a five-point scale. The number of
patients recruited into each of the five categories of radio-
logical density were as follows: <10%, n = 101; 10% to
<25%, n = 62; 25% to <50%, n = 60; 50% to <75%, n =
60; and ≥ 75%, n = 99.
Recruitment
Potential participants were sent a letter and subsequently
telephoned about the study. Premenopausal women were
eligible if they were menstruating regularly, not pregnant or
breast-feeding, and had not had a hysterectomy or
oophorectomy. Postmenopausal women were eligible if
they had spontaneous amenorrhea for at least 12 months,
or had had a hysterectomy and were 50 years of age or
older, or had had a bilateral oophorectomy at any age. A
woman was excluded if she was taking any type of exoge-
nous hormone preparation, had breast augmentation or
reduction, or had a personal history of breast cancer or was
being investigated for breast cancer. In total, 382 women
agreed to participate in the study, representing 88% of
those who were contacted and found to be eligible.
Measurements
Blood samples were collected after a 12-hour overnight
fast, and during the luteal phase of the menstrual cycle
(days 20–24) for premenopausal women. The mammo-
gram closest to the time of the blood draw was used (mean
difference 32 weeks). Twenty-four hour urine samples were
also collected.
Obtaining consent for the phenotyping study
Because examination of CYP1A2 activity in relation to
mammographic density was not a goal of the original study,
patients were subsequently mailed a letter describing the
goals of the phenotypic component of this study, and writ-
ten consent was obtained to phenotype CYP1A2 activity.
Information on ethnicity was also obtained at this time. Of
382 eligible women (193 premenopausal and 189 post-
menopausal), 357 (93%) gave consent. Eight women
could not be contacted because they had moved and could
not be traced through either telephone directories or their
physicians. Sixteen women were nonresponders after a
minimum of four telephone reminders, and one did not pro-
vide consent.
Of the 357 women, 40 (11.2%; 29 premenopausal and 11
postmenopausal) did not have urine samples and 22
(6.2%; seven premenopausal and 15 postmenopausal)
had insufficient excretion of caffeine metabolites for esti-
mating CYP1A2 activity, leaving 146 postmenopausal and
149 postmenopausal women in whom CYP1A2 activity
was measurable. This represented 93% of women with
urine samples and 82% of eligible women who provided
consent. The overall participation rate for this portion of the
study was 77% (295/382).
Ethnicity
By questionnaire, each participant was asked their country
of birth as well as the countries of birth for each of their par-
ents and grandparents. They were also asked the question,
'What is your ethnic or cultural background?' and were
given instructions to mark all appropriate categories. They
were classified as follows: black; white (e.g. British, French,
European, Latin/South American of European back-
ground); native/aboriginal people of North America (North
American Indian, Inuit, Métis); East Asian (e.g. Chinese,
Japanese, Korean, Vietnamese); South Asian (e.g. Indian
from India, Pakistani, Punjabi, Tamil); other, with specifica-
tion; and 'don't know'. Because of low numbers in groups
other than Caucasians, the categories were collapsed and
described as Caucasian (white), East Asians, Jewish, and
other.
Epidemiologic and anthropometric data
Information about epidemiologic risk factors for breast den-
sity and breast cancer was collected by questionnaire, and
dietary information was obtained using a list-based food
frequency questionnaire developed by Block and cowork-
ers [20]. Each woman was weighed and measured for
height, and waist and hip circumference.
CYP1A2 activity
Caffeine (1, 3, 7-trimethylxanthine) is metabolized by
CYP1A2 and has been used to evaluate CYP1A2 activity
in vivo [21]. The best urinary metabolic ratio appears to be
[5-acetylamino-6-formylamino-3-methyluracil (AFMU) + 1-
methylurate (1U) + 1-methylxanthine (1X)]/1,7-dimethylu-
rate (1, 7U), which is referred to as the caffeine metabolic
ratio (CMR) [22]. The CMR is not dependent on renal flow
[23], and is based only on metabolic end products of caf-
feine metabolism, thus making the amount and timing of
urine collection relatively unimportant [24]. Measurement of
the CMR in 24-hour urine samples has been shown to be a
viable method for assessing CYP1A2 intake in populations
with widespread caffeine use [25]. In the present study,
93% of women consumed sufficient levels of caffeine to
estimate CMR. Because daily caffeine intake is relativelyBreast Cancer Research    Vol 6 No 4    Hong et al.
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constant, urinary recovery of caffeine metabolites over a
24-hour period reflects CMRs observed with standardized
dosing [25].
Urinary caffeine metabolites were measured by HPLC as
previously described [21], except for a modification of the
composition of the mobile phase. The mobile phase was
composed of 1.3% isopropanol, 0.2% isonitrile, and 0.1%
phosphoric acid. The caffeine metabolites were eluted at 1
ml/min and detected by ultraviolet absorbance (0.05) at
280 nm. The retention times of 1U, 1X and 1, 7U and the
internal standard (N-acetyl-p-aminophenol) were 9.9, 11.9,
29.8, and 14.2 min, respectively.
Urinary AFMU was first deformylated to stable 5-
acetylamino-6-amino-3-methyluracil (AAMU) and then
measured using the HPLC method reported by Tang and
coworkers [21]. The mobile phase consisted of 0.075%
acetic acid and 0.075% phosphoric acid. AAMU and the
internal standard (hydrobenzyl alcohol) were eluted at a
flow of 0.9 ml/min and monitored by ultraviolet absorbance
(0.04) at 263 nm. The retention times of AAMU and the
internal standard were 13 and 36 min, respectively.
A standard urine sample with known caffeine metabolite
concentrations was analyzed across all days of sample
analyses with an interassay coefficient of variation of 9%.
Accuracy of the CYP1A2 measurement did not vary with
caffeine intake. After adjustment for smoking status, age,
body mass index (BMI), waist–hip ratio (WHR), and ethnic-
ity, coefficients of variation associated with mean CYP1A2
function across quartiles of caffeine intake were 56.8%,
55.3%, 57.0%, and 46.9% for premenopausal women, and
39.8%, 44.1%, 43.5%, and 42.4% for postmenopausal
women. Kashuba and coworkers [26] investigated the
intraindividual variability in CYP1A2 activity over a 3-month
period and the median coefficient of variation was 16.8%
(range 4.5–49.3%).
Serum antioxidants
Serum levels of α-tocopherol, retinol, and five commonly
reported carotenoids (α- and β-carotene, lutein, lycopene
and cryptoxanthin) were extracted using hexane and ana-
lyzed by reverse phase HPLC, C18 column, and absorb-
ance detector. Peaks were identified and quantified by
using their respective standards [27].
Serum MDA, urinary MDA, dG-MDA adducts
MDA in serum and urine was measured in triplicate by
HPLC determination of thiobarbituric acid derivatives, as
described by Bird and coworkers [28]. The sample was
extracted with trichloroacetic acid and then heated with
thiobarbituric acid. The thiobarbituric acid–MDA complex
was separated using HPLC and the absorbance measured
at 535 nm. Total urinary MDA level excreted over a 24-hour
period was calculated as concentration of urinary MDA
multiplied by total urinary volume collected. Study results
with total urinary MDA were similar to those obtained when
total urinary MDA levels were expressed per millimole cre-
atinine. Results shown here are those obtained with total
urinary MDA levels unadjusted for creatinine.
Precipitated DNA was treated with RNase A and RNase T1
to remove RNA contamination. Isolated DNA was hydro-
lyzed using nuclease P1 and alkaline phosphatase, and the
amount of dG-MDA adducts were determined by reverse-
phase HPLC, C18 column, and fluorescence detection
(340 nm excitation, 518 nm emission) using 30% as the
mobile phase, as previously described [29].
Serum estradiol
Serum estradiol levels in premenopausal women were
measured at the London Regional Cancer Center in
Ontario, Canada in the laboratory of Geoffrey Hammond
[30]. Serum estradiol levels in postmenopausal women
were measured by Esoterix Center for Clinical Trials (Cala-
basas Hills, California, USA) [19].
Mammographic density
Breast density measurements were made using a randomly
selected, craniocaudal (viewing from above, down) mam-
mographic view of one breast from each woman. Mammo-
grams were digitized using a Lumisys model 85 (Eastman
Kodak Company, Rochester, NY, USA) and randomly
ordered for analysis. The observer (NFB) selected a thresh-
old gray value to separate the image of the breast from the
background. A second threshold was selected to identify
the edges of regions representative of radiographically
dense tissue. Summation of pixels within these areas gave
a measure of the area of density in the breast. The percent-
age of radiographic density is the area of dense tissue
divided by the entire projected area of the breast multiplied
by 100. Further details of this method are given elsewhere
[31].
Statistical methods
Data analyses were carried out using the SAS statistical
software package (version 6.12; SAS Institute Inc., Cary,
NC, USA) [32]. Data were inspected for normality and,
when necessary, transformed to approximate a normal dis-
tribution. This included square root transformation of per-
centage breast density, and natural log transformation of
CYP1A2 activity, BMI, and MDA levels. Because of differ-
ences in results between premenopausal and postmeno-
pausal women, all data are presented stratified by
menopausal status.
Partial correlations were used to control for potential con-
founders when relationships between serum, urinary, and
dG-MDA levels were assessed.Available online http://breast-cancer-research.com/content/6/4/R338
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Relationships between CYP1A2 phenotype, MDA levels,
and breast density were assessed using multiple regres-
sion analysis. For descriptive purposes, relationships
across quartiles were also provided with a test for trend.
Although these results are based on analyses of trans-
formed data, they are presented in their original units with
95% confidence intervals. Age, BMI, WHR, ethnicity, and
smoking status were included in all models unless indi-
cated. Age and body size were included as potential con-
founders because increased oxidant status and lipid
peroxidation is related to advancing age, central obesity,
hyperinsulinemia, insulin resistance, dyslipidemia, and
blood glucose [33-36]. In the present study, serum MDA
levels were positively associated with BMI measurements
in both premenopausal and postmenopausal women (P ≤
0.005). Age and body size are also important determinants
of breast density levels [1]. Adjustments were made for
smoking status because tobacco smoke is inversely asso-
ciated with mammographic density [37] and is a known
inducer of CYP1A2 activity [38]. Associations between
CYP1A2 and MDA levels, as well as associations between
MDA levels and mammographic density, were further
adjusted for serum antioxidant levels.
To illustrate interactions between CYP1A2 activity and
MDA levels (i.e. two continuous variables) on percentage
density, relationships (simple slopes) between CYP1A2
activity and percentage density were determined for (con-
ditional on) three levels of oxidative stress: at mean level, at
one standard deviation above the mean, and one standard
deviation below the mean [39].
Of 295 women with CYP1A2 results, 251 (85%) were
non-Jewish Caucasians, 10 were East Asians, 15 were
Jewish, and 19 were from other ethnic groups. To assess
the possibility that ethnicity may be a potential confounder
of findings, all analyses were performed on the 295 women
with CYP1A2 results, with and without adjustment for eth-
nicity. All analyses were then repeated with only the 251
non-Jewish Caucasians. Findings from all three sets of
analyses were similar, suggesting that ethnicity was not a
strong confounder in the study. Results shown in this report
are those performed on the 295 women with adjustment for
ethnicity.
Results
Study subject characteristics
There were 146 premenopausal and 149 postmenopausal
women with CYP1A2 phenotype data, for whom selected
characteristics are shown in Table 1. Of the participants
85% were Caucasian, 3.4% were East Asian, 5.1% were
Jewish, and 6.4% were from other ethnic groups. The mean
age was 45 years in premenopausal and 56 years in post-
menopausal women. The two groups were similar in age at
menarche, age at first birth, and total number of livebirths.
Postmenopausal women were slightly heavier, with higher
average BMI and WHR. They also had lower levels of per-
centage mammographic density, and higher serum and uri-
nary MDA levels.
Compared with Caucasians, premenopausal and postmen-
opausal East Asian women and premenopausal Jewish
women were lighter, with lower mean BMIs and greater lev-
els of percentage breast density. Among premenopausal
women, East Asians had higher levels of urinary MDA than
did Caucasians. In postmenopausal women, compared
with Caucasians, East Asians were older at age of first
birth, and had higher levels of CYP1A2 activity and urinary
MDA. Jewish women had lower CYP1A2 activity than did
Caucasians.
In premenopausal women, those without CYP1A2 data
had higher urinary MDA levels than did those with pheno-
type data. In postmenopausal women, those without
CYP1A2 results weighed less, and had lower mean BMI
and urinary MDA levels. Percentage density was on aver-
age 14% higher in these patients than in women with
CYP1A2 results.
CYP1A2 activity
The CMR in premenopausal women ranged from 0.8 to
23.5, with a mean ± standard deviation of 6.2 ± 2.9 and a
median of 5.8. In postmenopausal women the ratio ranged
from 1.8 to 17.1, with a mean ± standard deviation of 5.9
± 2.3, and median of 5.4. This magnitude of interindividual
variation is similar to those in previous reports showing up
to a 30-fold variation in enzyme activity [40,41]).). The pop-
ulation distribution of CMR in the present study was log-
normal, which is similar to findings of other studies using
the same urinary ratio [25,38,40,41].
MDA measures
Postmenopausal women had higher serum (F = 18.08, P <
0.0001) and urinary (F = 24.05, P < 0.0001) MDA levels
than did premenopausal women, but dG-MDA levels were
not different between the two groups (P = 0.41). These
findings were not altered when further adjusted for age,
BMI, and WHR. The coefficient of variation associated with
each MDA measure (untransformed values) was higher in
premenopausal than in postmenopausal women (41.4 ver-
sus 37.0 for serum MDA; 52.1 versus 44.6 for urinary
MDA; and 76.2 versus 56.0 for dG-MDA).
In premenopausal women, serum and urinary MDA levels
were weakly correlated before (r = 0.15, P = 0.08) and
after (r = 0.21, P = 0.02) adjustment for age, BMI, and
WHR. Neither measure, however, was correlated with dG-
MDA levels (P > 0.28). In postmenopausal women, serum
MDA levels were positively associated with urinary (r =
0.17, P = 0.03) and dG-MDA (r = 0.17, P = 0.04) levels.Breast Cancer Research    Vol 6 No 4    Hong et al.
R343
Table 1
Selected characteristics of study subjects by ethnicity and menopausal status
With CYP1A2 results No CYP1A2 
results5
Caucasian1:
pre (n = 125);
post (n = 126)
East Asian2:
pre (n = 4);
post (n = 6)
Jewish3:
pre (n = 10);
post (n = 5)
Other4:
pre (n = 7);
post (n = 12)
Pre (n = 36);
post (n = 26)
Premenopausal
Risk factors
Age (years) 44.8 (4.8) 46.8 (4.5) 45.4 (3.1) 44.7 (5.1) 45.1 (4.4)
Weight (kg) 68.1 (16.6) 54.8 (3.1) 59.4 (10.7) 64.9 (17.9) 69.1 (13.3)
BMI (kg/m2) 25.3 (6.1) 23.2 (0.9) 22.6 (3.5) 25.9 (6.5) 25.8 (5.1)
WHR 0.75 (0.06) 0.75 (0.04) 0.73 (0.07) 0.77 (0.05) 0.74 (0.06)
Age at menarche (years) 12.8 (1.5) 11.5 (1.3) 12.2 (0.6) 13.7 (1.6) 12.6 (1.5)
Age at first birth (years) 27.8 (5.7) 29.5 (0.7) 29.5 (2.7) 25.6 (9.7) 29.0 (6.4)
Number of live births 1.4 (1.2) 1.0 (1.2) 2.1 (1.3) 1.6 (1.3) 1.5 (1.2)
Mammographic density (%)6 27.4 (23.2) 47.6 (17.0) 40.2 (22.7) 25.9 (20.0) 28.4 (20.5)
CYP1A2 activity7 6.31 (2.95) 6.52 (0.98) 4.98 (1.04) 6.11 (3.50) -
Markers of oxidative stress
Serum MDA (µmol/l) 1.47 (0.58) 1.52 (0.47) 1.53 (1.05) 1.77 (0.68) 1.45 (0.66)
Urinary MDA (µmol/day) 2855.3 (1514.1) 3591.6 (1365.9) 2813.0 (1392.2) 2293.9 (1116.9) 3729.4 (1365.9)
dG-MDA (ρmol/mg DNA) 200.8 (157.9) 232.8 (115.7) 221.4 (164.6) 169.31 (76.27) 180.2 (135)
Postmenopausal
Risk factors
Age (years) 56.3 (4.6) 54.8 (3.8) 53.4 (2.5) 55.9 (4.2) 56.0 (4.5)
Weight (kg) 72.5 (16.6) 55.8 (9.8) 70.5 (18.1) 66.6 (15.7) 63.7 (17.0)
BMI (kg/m2) 26.8 (6.2) 23.2 (4.7) 25.9 (6.8) 25.6 (5.4) 23.3 (5.2)
WHR 0.77 (0.07) 0.77 (0.08) 0.80 (0.09) 0.80 (0.06) 0.75 (0.11)
Age at menarche (years) 13.1 (1.6) 13.0 (1.7) 12.6 (2.6) 13.0 (2.1) 12.8 (1.70)
Age at menopause (years) 49.1 (4.8) 50.8 (3.3) 49.1 (3.7) 48.8 (2.5) 48.2 (4.3)
Age at first birth (years) 26.0 (5.2) 34.6 (6.8) 22.8 (3.8) 31.0 (8.7) 25.4 (4.1)
Number of live births 1.8 (1.5) 1.8 (1.5) 2.2 (1.6) 1.0 (1.0) 1.4 (1.4)
Mammographic density (%)6 19.8 (18.5) 48.2 (8.9) 22.3 (24.6) 30.1 (23.8) 36.0 (22.1)
CYP1A2 activity7 5.73 (2.18) 8.86 (1.83) 3.49 (1.75) 6.64 (2.81) -
Markers of oxidative stress
Serum MDA (µmol/l) 1.75 (0.65) 1.83 (0.59) 1.69 (0.74) 1.64 (0.7) 1.84 (0.72)
Urinary MDA (µmol/day) 3518.5 (1587.5) 4636.2 (1348.3) 3412.9 (978.9) 3717.0 (1926.2) 2449.3 (1301.8)
dG-MDA (ρmol/mg DNA) 197.7 (112.6) 149.9 (107.2) 158.2 (108.1) 212.9 (80.8) 203.2 (109.6)
Values are expressed as mean (standard deviation). 1Premenopausal (pre): n = 86 for age at first birth, n = 120 for urinary malondialdehyde 
(MDA), and n = 121 for malondialdehyde–deoxyguanosine (dG-MDA). Postmenopausal (post): n = 117 for menopausal age, n = 97 for age at 
first birth, and n = 123 for dG-MDA. 2Pre: n = 2 for age at first birth. Post: n = 5 for age at first birth. 3Pre: n = 8 for age at first birth and n = 9 for 
dG-MDA. Post: n = 4 for age at first birth and dG-MDA. 4Pre: n = 5 for age at first birth. Post: n = 11 for menopausal age and n = 8 for age at first 
birth. 5Pre: n = 25 for age at first birth, n = 7 for urinary MDA, and n = 34 for dG-MDA. Post: n = 23 for age at menopause, n = 14 for age at first 
birth, n = 15 for urinary MDA, and n = 25 for dG-MDA. 6Proportion of breast area occupied by dense tissue. 7Estimated by caffeine metabolic 
ratio (see text for details). BMI, body mass index; CYP1A2, cytochrome P450 1A2; WHR, waist–hip ratio.Available online http://breast-cancer-research.com/content/6/4/R338
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After adjustment for age, BMI, and WHR, serum MDA con-
tinued to be associated with dG-MDA (r = 0.19, P = 0.02),
but it was only weakly associated with urinary MDA levels
(r = 0.14, P = 0.09). Urinary and dG-MDA levels were not
correlated (P ≥ 0.13).
CYP1A2 activity and mammographic density
Relationships between CYP1A2 activity and percentage
mammographic density levels are shown in Table 2.
Results were initially adjusted for age, ethnicity, and smok-
ing. Findings were then further adjusted for total estrogen
levels to determine whether CYP1A2 function was inde-
pendently associated with breast density levels without the
influence of estrogen. Finally, findings were further adjusted
for age at menarche, age at menopause (in postmenopau-
sal women only), number of livebirths, BMI, WHR, family
history of breast cancer, and smoking status.
CMR, as an indicator of CYP1A2 activity, was not related
to percentage density in premenopausal women after
adjustment for age, ethnicity, and smoking (P = 0.58), total
estrogen (P = 0.49), and other common covariates (P =
0.68). In contrast, CMR in postmenopausal women was
positively related to percentage breast density after adjust-
ment for age, ethnicity, and smoking (β = 1.57 ± 0.60, F =
6.89, P = 0.01) as well as total estrogen (β = 1.30 ± 0.64,
F = 4.05, P = 0.05). The relationship was attenuated and
no longer significant when further adjusted for other risk
factors for breast density (β = 0.94 ± 0.64, F = 2.36, P =
0.13), although the P  trend remained significant across
quartiles of CMR (P  = 0.05). The positive association
between CMR and breast density was primarily due to a
lower mean percentage density level in the first quartile of
CMR.
CYP1A2 activity and malondialdehyde levels
Relationships between CYP1A2 activity and MDA levels
are shown in Table 3. CYP1A2 activity was positively asso-
ciated with serum (P = 0.03) and urinary (P = 0.04) MDA
levels in premenopausal but not in postmenopausal women
(P ≥ 0.58). These relationships in premenopausal women
were not altered when further adjusted for serum levels of
the antioxidants tocopherol, retinol, β-carotene, β-cryptox-
anthin, lycopene, and lutein (serum MDA: P = 0.04; urinary
MDA: P = 0.04). No relationships were observed between
CYP1A2 activity and dG-MDA levels in either menopausal
group before (P ≥ 0.34) or after adjustment (P ≥ 0.32) for
serum antioxidant levels.
MDA levels and mammographic density
Relationships between MDA levels and percentage breast
density are shown in Table 4. No associations were
observed between serum, urinary, or dG-MDA levels and
percentage breast density in either premenopausal or post-
menopausal women after adjustment for age, ethnicity,
BMI, WHR, and smoking status. Further adjustments for
serum antioxidant levels did not alter these findings. How-
ever, in premenopausal and postmenopausal women com-
bined, we observed a positive association between urinary
MDA levels and percentage mammographic density when
adjusted for age, ethnicity, weight (instead of BMI), WHR,
smoking status, and menopausal status (β = 0.47 ± 0.22,
F = 4.45, P = 0.04). With further adjustment for serum anti-
oxidant levels, however, the relationship was no longer sig-
Table 2
CYP1A2 activity and mammographic density
Quartiles of CMR: mean percentage density (95% confidence interval)
Model adjustments CMR: β (SE)1 F P Q1 Q2 Q3 Q4 P for 
trend
Premenopausal (n = 146)3
Age, ethnicity, smoking2 0.29 (0.52) 0.31 0.58 26.7 (14.5–42.6) 28.4 (16.9–42.8) 30.7 (19.0–45.2) 29.9 (17.9–45.0) 0.57
+ total estrogen 0.36 (0.52) 0.48 0.49 26.1 (13.8–42.3) 28.0 (16.5–42.5) 30.2 (18.4–44.8) 30.3 (18.0–45.8) 0.49
+ other covariates -0.16 (0.38) 0.17 0.68 20.1 (10.3–33.1) 20.9 (11.7–32.8) 21.2 (12.4–32.2) 18.5 (10.0–29.6) 0.72
Postmenopausal (n = 149)4
Age, ethnicity, smoking 1.57 (0.60) 6.89 0.01 14.1 (6.6–24.3) 30.2 (18.4–45.1) 24.8 (14.7–37.5) 31.0 (20.9–43.2) 0.01
+ total estrogen 1.30 (0.64) 4.05 0.05 12.8 (5.6–22.9) 27.2 (15.7–41.7) 22.5 (12.9–34.8) 27.4 (17.6–39.4) 0.03
+ other covariates 0.94 (0.61) 2.36 0.13 14.6 (5.7–27.6) 25.0 (13.0–41.0) 19.0 (8.6–33.5) 28.2 (15.8–44.1) 0.05
1β associated with log transformed caffeine metabolic ratio (CMR) as the independent variable and square-root transformed percentage breast 
density as the dependent variable. 2Statistical models are initially adjusted for age, ethnicity, and smoking status. Models are subsequently 
adjusted for total estrogen, and then for other covariates, which include adjustments for age at menarche, age at menopause (postmenopausal 
only), number of live births, body mass index (BMI), waist–hip ratio (WHR), and family history of breast cancer. 3n = 144 for estrogen adjusted 
analysis and n = 143 for covariate adjusted analysis. 4n = 127 for estrogen adjusted analysis and n = 118 for covariate adjusted analysis.Breast Cancer Research    Vol 6 No 4    Hong et al.
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nificant (β = 0.35 ± 0.23, F = 2.29, P  = 0.13). The
relationship was also attenuated slightly when height was
further added to the model (β = 0.35 ± 0.22, F = 2.62, P =
0.11). If all women who participated in the original study
were included, including those without CYP1A2 results,
then the positive association observed between urinary
MDA levels and breast density after adjustment for age,
weight, smoking status, WHR, and menopausal status was
significant (n = 335; β = 0.53 ± 0.22, F = 5.67, P = 0.02),
even after adjustment for height (β = 0.44 ± 0.22, F = 3.97,
P  = 0.05), but not with further adjustment for serum
antioxidant levels (β = 0.31 ± 0.23, F = 1.85, P = 0.18).
Similarly, among all women there was a positive association
between urinary MDA and breast density if adjustment was
for waist circumference (the anthropometric variable most
closely associated with breast density levels), smoking sta-
tus, height, and menopausal status (β = 0.44 ± 0.22, F =
4.06, P = 0.04). The relationship was attenuated by further
adjustment for serum antioxidant levels (β = 0.32 ± 0.22, F
= 2.10, P = 0.15).
Interaction between CYP1A2 activity and MDA levels
Although not originally hypothesized, we tested for possi-
ble interactions between CYP1A2 function and MDA levels
with respect to mammographic density. Relationships
between CYP1A2 activity and mammographic density
according to MDA levels are shown in Fig. 2. Although not
statistically significant, interactions in premenopausal
Table 3
CYP1A2 activity and malondialdehyde levels
Quartiles of CMR: mean MDA (95% confidence interval)
CMR1β 
(SE)
F P Q1 Q2 Q3 Q4 P for
trend
Premenopausal (n = 146)3
Serum MDA (µmol/l)1 0.15 (0.07) 4.59 0.03 1.37
(1.15–1.63)
1.52
(1.30–1.77)
1.50
(1.28–1.74)
1.62
(1.38–1.91)
0.06
Serum MDA adjusted for 
antioxidants (µmol/l)2
0.14 (0.07) 4.23 0.04 1.33
(1.12–1.57)
1.39
(1.19–1.62)
1.47
(1.27–1.71)
1.53
(1.31–1.79)
0.05
Total urinary MDA (µmol/
day)1
0.23 (0.11) 4.24 0.04 2.35
(1.81–3.06)
2.44
(1.92–3.09)
3.06
(2.44–3.84)
2.78
(2.18–3.53)
0.06
Total urinary MDA 
adjusted for antioxidants 
(mol/day)
0.24 (0.11) 4.36 0.04 2.33
(1.78–3.05)
2.37
(1.81–3.09)
2.90
(2.29–3.68)
2.75
(2.14–3.54)
0.08
dG-MDA (ρ mol/mg DNA)1 -0.13 (0.15) 0.72 0.40 186.8
(126.5–275.9)
160.1
(112.5–227.6)
157.0
(111.6–220.8)
153.6
(106.9–220.6)
0.29
dG-MDA adjusted for 
antioxidants (ρ mol/mg 
DNA)
-0.09 (0.16) 0.35 0.55 187.2
(126.0–278.1)
164.7
(115.0–235.7)
143.9
(101.7–203.6)
163.0
(113.0–235.2)
0.35
Postmenopausal (n = 149)4
Serum MDA (µmol/l)1 -0.00 (0.09) 0.00 0.99 1.73
(1.45–2.07)
1.63
(1.36–1.95)
1.55
(1.31–1.83)
1.72
(1.49–1.99)
0.86
Serum MDA adjusted for 
antioxidants (µmol/l)
0.08 (0.09) 0.73 0.39 1.71
(1.42–2.04)
1.66
(1.38–1.99)
1.62
(1.35–1.94)
1.81
(1.55–2.1 0)
0.52
Total urinary MDA (µmol/
day)1
-0.06 (0.11) 0.31 0.58 4.06
(3.24–5.09)
3.75
(2.97–4.72)
3.77
(3.05–4.65)
3.69
(3.62–3.76)
0.43
Total urinary MDA 
adjusted for antioxidants 
(µmol/day)
-0.12 (0.11) 1.11 0.29 4.02
(3.20–5.04)
3.82
(3.03–4.80)
4.08
(3.25–5.11)
3.70
(3.06–4.47)
0.20
dG-MDA (ρ mol/mg DNA)1 0.16 (0.16) 0.93 0.34 141.2
(101.4–196.6)
135.1
(96.6–188.9)
133.9
(98.2–182.5)
156.8
(119.4–205.9)
0.57
dG-MDA adjusted for 
antioxidants (ρ mol/mg 
DNA)
0.17 (0.17) 0.98 0.32 153.7
(109.3–216.2)
143.9
(101.9–203.2)
147.1
(105.2–205.6)
167.0
(125.4–222.3)
0.56
1Log transformed. All statistical models are adjusted for age, ethnicity, body mass index (BMI), waist–hip ratio (WHR), and smoking status. 
2Models are further adjusted for serum levels of the antioxidants tocopherol, retinal, β-carotene, β-cryptoxanthin, lycopene, and lutein. 3n = 143 for 
serum malondialdehyde (MDA) with adjustment for antioxidants; n = 141 for urinary MDA and n = 138 with adjustment for antioxidants; and n = 
141 for malondialdehyde–deoxyguanosine (dG-MDA) adducts and n = 139 with adjustment for antioxidants. 4n = 145 for dG-MDA. CMR, 
caffeine metabolic ratio.Available online http://breast-cancer-research.com/content/6/4/R338
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women were suggested for urinary MDA (F = 2.14, P =
0.15) and dG-MDA adducts (F = 2.97, P = 0.09) after
adjusting for age, ethnicity, BMI, WHR, and smoking status.
The interaction between dG-MDA adducts and CYP1A2
activity was statistically significant if an adjustment was
made for weight instead of BMI (F = 4.67, P = 0.03). This
interaction was slightly attenuated if a further adjustment
was made for height (F = 3.36, P = 0.07). For both MDA
measures, the associations between CYP1A2 activity and
breast density were more negative at low levels of MDA,
and became more positive as MDA levels increased. At low
dG-MDA adduct levels (illustrated at -1 standard devia-
tion), for example, there was a negative nonsignificant rela-
tionship between CYP1A2 activity and percentage breast
density (β = -0.77 ± 0.50, F = 2.36, P = 0.13). At mean
MDA level CYP1A2 activity was not associated with breast
density (β = -0.03 ± 0.40, F = 0.00, P = 0.95), and at high
levels of dG-MDA (illustrated at +1 standard deviation)
there was a positive nonsignficant association between
CYP1A2 activity and breast density (β = 0.72 ± 0.66, F =
1.16, P = 0.28). A similar but nonsignificant (P = 0.29) pat-
tern of interaction between CYP1A2 function and serum
MDA levels were observed for postmenopausal women,
although in the instance of urinary MDA the pattern was
reversed. Those with lower MDA levels showed more
positive associations between CYP1A2 function and
breast density levels (P = 0.35).
Table 4
Malondialdehyde levels and mammographic density
Quartiles of MDA: mean percentage density (95% confidence interval)
MDA1β (SE) F P Q1 Q2 Q3 Q4 P for 
trend
Premenopausal (n = 146)3
Serum MDA (µmol/l) 0.57 (0.46) 1.52 0.22 26.1
(17.7–36.1)
25.7
(17.0–36.1)
27.2
(18.9–36.9)
26.3
(18.1–36.0)
0.89
Serum MDA adjusted for 
antioxidants (µmol/l)2
0.12 (0.51) 0.06 0.81 28.4
(19.3–39.1)
25.8
(17.0–36.5)
23.6
(15.7–33.0)
22.9
(15.0–32.6)
0.26
Total urinary MDA (µmol/day) 0.24 (0.32) 0.60 0.44 23.5
(15.5–33.2)
27.9
(18.5–39.2)
25.3
(17.6–34.4)
26.9
(18.5–36.8)
0.61
Total urinary MDA adjusted 
for antioxidants (µmol/day)
0.17 (0.33) 0.27 0.61 21.9
(14.0–31.5)
26.5
(17.2–37.9)
25.3
(17.4–34.7)
24.3
(16.1–34.3)
0.70
dG-MDA (ρ mol/mg DNA) -0.02 (0.22) 0.01 0.94 18.8
(12.1–27.0)
32.7
(22.8–44.4)
31.5
(22.4–42.0)
23.0
(15.7–31.8)
0.91
dG-MDA adjusted for 
antioxidants (ρ mol/mg 
DNA)
0.10 (0.23) 0.18 0.67 19.8
(12.6–28.5)
32.8
(22.4–45.1)
28.2
(19.4–38.7)
23.6
(15.9–32.8)
0.58
Postmenopausal (n = 149)4
Serum MDA (µmol/l) -0.33 (0.49) 0.47 0.49 21.3
(13.4–31.1)
24.7
(16.5–34.5)
22.4
(14.1–32.7)
21.2
(13.6–30.4)
0.84
Serum MDA adjusted for 
antioxidants (µmol/l)
-0.37 (0.52) 0.52 0.47 22.3
(13.2–33.9)
25.4
(16.8–35.7)
23.4
(14.4–34.5)
21.8
(13.7–31.9)
0.77
Total urinary MDA (µmol/day) 0.19 (0.39) 0.24 0.63 25.1
(16.3–35.8)
19.1
(11.5–28.7)
29.5
(20.5–40.2)
24.5
(11.6–34.0)
1.00
Total urinary MDA adjusted 
for antioxidants (µmol/day)
-0.04 (0.41) 0.01 0.93 27.6
(17.9–39.6)
19.8
(11.5–30.3)
21.4
(13.5–31.1)
24.7
(16.4–34.7)
0.65
dG-MDA (ρ mol/mg DNA) -0.05 (0.28) 0.04 0.85 22.6
(14.9–32.1)
22.8
(14.1–33.5)
24.2
(15.2–35.2)
23.3
(14.8–33.7)
0.86
dG-MDA adjusted for 
antioxidants (ρ mol/mg 
DNA)
-0.11 (0.29) 0.14 0.71 23.2
(14.7–33.6)
23.5
(14.4–34.8)
25.8
(16.1–37.8)
21.9
(13.5–32.4)
0.87
1β associated with log transformed malondialdehyde (MDA) levels as the independent variable and square-root transformed percentage breast 
density as the dependent variable. All statistical models are adjusted for age, ethnicity, body mass index, waist–hip ratio, and smoking status. 
2Models are further adjusted for serum levels of the antioxidants tocopherol, retinal, β-carotene, β-cryptoxanthin, lycopene, and lutein. 3n = 143 for 
serum MDA with adjustment for antioxidants; n = 141 for urinary MDA and n = 138 with adjustment for antioxidants; and n = 141 for 
malondialdehyde–deoxyguanosine (dG-MDA) adducts and n = 139 with adjustment for antioxidants. 4n = 145 for dG-MDA. CMR, caffeine 
metabolic ratio.Breast Cancer Research    Vol 6 No 4    Hong et al.
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Figure 2
Relationships between cytochrome P450 1A2 (CYP1A2) activity and percentage breast density according to (a) serum and (b) urinary malondialde- hyde (MDA) levels, and (c) malondialdehyde–deoxyguanosine (dG-MDA) levels Relationships between cytochrome P450 1A2 (CYP1A2) activity and percentage breast density according to (a) serum and (b) urinary malondialde-
hyde (MDA) levels, and (c) malondialdehyde–deoxyguanosine (dG-MDA) levels. All analyses are adjusted for age, ethnicity, body mass index (BMI), 
waist–hip ratio (WHR), and smoking status. Confounders were set at mean values and determined for Caucasian nonsmokers to illustrate relation-
ships between CYP1A2 activity and percentage density according to MDA levels. Number of women in each group: premenopausal, n = 146 for 
serum MDA and n = 141 for urinary MDA and dG-MDA; and postmenopausal, n = 149 for serum and urinary MDA and n = 145 for dG-MDA. CMR, 
caffeine metabolic ratio.Available online http://breast-cancer-research.com/content/6/4/R338
R348
Discussion
In premenopausal women, CYP1A2 activity, as estimated
by the CMR, was not associated with breast density levels
but was positively related to serum and urinary MDA levels.
In postmenopausal women, higher CYP1A2 activity was
consistently associated with higher levels of breast density,
suggesting that increased CYP1A2 activity in this group is
a risk factor for breast cancer. No associations, however,
were observed between CYP1A2 activity and MDA levels.
In postmenopausal women, relationships were consistently
positive between CYP1A2 activity and breast density lev-
els. These observations are consistent with the findings of
Riza and coworkers [42], who found that postmenopausal
women with dense parenchymal breast patterns had 58%
higher levels of 2-hydroxyestrone than did women with no
density. Prospectively, however, both a higher [43] and a
lower [44] ratio of 2-hydroxyestrone to 16α-hydroxyestrone
have been associated with increased risk for breast cancer
in postmenopausal women.
The positive relationship between CYP1A2 function and
breast density levels in postmenopausal women was
slightly attenuated by adjustment for total estradiol levels,
but it remained statistically significant. This finding sug-
gests that the relationship between CYP1A2 function and
breast density is partially mediated by circulating estradiol
levels, but that other factors are also important, such as cat-
echolestrogens and other products of CYP1A2 activity.
CYP1A2 is known to activate several heterocyclic and aro-
matic amine promutagens [15,45,46] as well as tobacco
smoke-specific nitrosamines [47]. The enzyme is also
inducible, and previous studies have shown variation in
activity by sex, race, age, smoking status, body mass index,
coffee and alcohol consumption, and exposure to various
combustion products and contaminants [15,38,48-52].
Although CYP1A2 activity was not associated with breast
density levels in premenopausal women, there was some
evidence that the relationship may be modulated by oxida-
tive burden. CYP1A2 activity was positively associated
with breast density when urinary and dG-MDA levels were
high and negatively associated when MDA levels were low.
These relationships, however, did not reach statistical sig-
nificance because of small sample size and the choice of
confounders included in the statistical model. The interac-
tion between dG-MDA adduct levels and CYP1A2 activity
on breast density levels, for instance, was statistically sig-
nificant when adjusted for weight instead of BMI.
An interaction between CYP1A2 activity and oxidative
stress is biologically plausible because CYP1A2 metabo-
lism of endogenous and exogenous substrates produce
reactive oxygenated metabolites [53]. In premenopausal
but not in postmenopausal women, we observed positive
associations between CYP1A2 activity and serum and uri-
nary MDA levels, as measures of lipid peroxidation.
CYP1A2 function has also been positively associated with
urinary excretion of 8-oxo-7,8-dihydro-2'-deoxyguanosine
which is a biomarker of oxidative DNA damage [54-56].
In premenopausal women, the observed interaction
between CYP1A2 activity and oxidative burden may result
from competing consequences. Against a background of
low oxidative burden, increased CYP1A2 function may
reflect the advantages of estrogen inactivation [17], with
attendant increases in reactive oxygen species being inac-
tivated by protective antioxidant systems. Against a back-
ground of high oxidative stress, however, the
disadvantages associated with further increases in pro-oxi-
dant levels may outweigh the benefits of increased estra-
diol inactivation.
An association between urinary MDA levels and mammo-
graphic density has been reported in two separate studies
[5,6]. We, however, did not replicate the observation when
premenopausal and postmenopausal women were consid-
ered separately [5]. This was due to our choice of con-
founders and to our limited sample size. A statistically
significant association was observed when premenopausal
and postmenopausal women were combined and results
were adjusted for weight or waist circumference instead of
BMI. The association was slightly attenuated by further
adjustment for height as a potential confounder and
remained significant if sample size was maximized to
include all women in the original study. Further adjustments
for serum antioxidant levels, however, attenuated these
relationships.
The weak and null associations observed between MDA
measures and breast density may be partly due to con-
founding by correlates of body size. Increased pro-oxidant
activity is related to central obesity, hyperinsulinemia, insu-
lin resistance, dyslipidemia, and blood glucose levels [33-
36]. In this study, both serum and urinary MDA levels were
positively associated with BMI and weight. BMI and WHR,
however, are inversely associated with breast density levels
[1]. Thus, MDA and mammographic density may seem
inversely related if not properly adjusted for body size and
its correlates. In our study, serum MDA levels after adjust-
ment for age and ethnicity was inversely associated with
mammographic density levels in both premenopausal (β =
-1.07 ± 0.61, F = 3.08, P = 0.08) and postmenopausal (β
= -1.29 ± 0.58, F = 5.02, P = 0.03) women. With further
adjustments for body size (BMI and WHR) and smoking
status, the relationship between MDA levels and breast
density became more positive in both premenopausal (β =
0.57 ± 0.46, F = 1.52, P = 0.22) and postmenopausal (β
= -0.33 ± 0.49, F = 0.47, P = 0.49) women, although nei-
ther was statistically significant.Breast Cancer Research    Vol 6 No 4    Hong et al.
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Weak correlations between various MDA measurements
may in part explain why these measures show different find-
ings. This is consistent with previous observations that
markers of oxidative DNA damage and lipid peroxidation
may not be strongly correlated, and suggests that no single
measure can be used as an indicator of in vivo oxidative
stress [57]. MDA levels are determined by a number of fac-
tors apart from endogenous lipid peroxidation. Exogenous
dietary intake, for instance, is estimated to represent 10–
18% [58] and as high as 50–60% [59] of urinary MDA lev-
els [60,61], and is difficult to adjust for in data analysis
because the MDA content of foods varies widely and is
affected by lipid type, storage, and cooking methods.
Regarding dG-MDA levels, it has recently been demon-
strated that these adducts can be formed independently of
lipid peroxidation through direct DNA oxidation [62]. Low
correlations between dG-MDA levels and lipid peroxidation
rates may also arise if MDA adduct levels are low enough
for complete repair [63], and it has further been suggested
that the relationship between circulating MDA concentra-
tions and MDA adducts may be relatively weak because
MDA is generated predominantly in cell membranes, some
distance from cellular DNA [64].
Limitations of the present study include small sample size,
which reduced our ability to detect interaction effects.
Another limitation of the study was that catecholestrogen
levels were not measured, therefore preventing
examination of individual catecholestrogen levels along
with levels of oxidative stress and breast density.
Conclusion
Results from the present study suggest that CYP1A2 activ-
ity is related to mammographic density levels and oxidative
stress, but that the nature of the relationship depends on
menopausal status. These findings provide further evi-
dence that variation in the level of activity of enzymes
involved in estrogen metabolism is related to breast density
levels and potentially breast cancer risk [65].
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